Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3

Conditions

Breast Neoplasms 355Neoplasms 252Carcinoma, Non-Small-Cell Lung 199Colorectal Neoplasms 181Lung Neoplasms 151Prostatic Neoplasms 150Carcinoma, Hepatocellular 127Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 82Neoplasm Metastasis 73Recurrence 72Uterine Cervical Neoplasms 68Rectal Neoplasms 68Ovarian Neoplasms 65Stomach Neoplasms 64Triple Negative Breast Neoplasms 59Squamous Cell Carcinoma of Head and Neck 57Brain Neoplasms 56Head and Neck Neoplasms 55Glioblastoma 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 48Melanoma 45Endometrial Neoplasms 43Disease 43Esophageal Neoplasms 42Hematologic Neoplasms 41Glioma 41Colonic Neoplasms 41

Interventions

famitinib 2camrelizumab 2toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Cervical Cancer Metastatic × 1 year × Clear all
NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Shanghai Jiatan Pharmatech Co., Ltd

Phase 3 Not yet recruiting
440 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT07266350 2025-12-05

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Chongqing University Cancer Hospital

Not yet recruiting
1,300 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
120 enrolled
Gynecologic

Cervical Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡